Comparison of Bortezomib Versus Lenalidomide Maintenance Therapy in Newly-Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Phase III GMMG-HD4 and -MM5 Trials

Maintenance therapy (MT) in newly-diagnosed, transplant-eligible multiple myeloma (MM) is a standard of care. Comparisons of single agent MT from distinct substance classes are not available. The present retrospective study analyzed post-transplant MT for 2 years with either bortezomib (BTZ) or lenalidomide (LEN) from two subsequently conducted, multicenter phase III trials (HD4/MM5) of the German-speaking Myeloma Multicenter Group (GMMG). Patients and